ArticleFrontiers in oncology2025
Role of transumbilical laparoendoscopic single-site surgery in the implementation ERAS in gynecology oncology: a retrospective study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Clinical efficacy and outcomes of enhanced recovery after surgery for laparoscopic cervical cancer.Biomedical reports · 2026Article
- Efficacy and safety of transumbilical laparoendoscopic single site surgery for mid-pregnancy ovarian cyst torsion: a retrospective analysis.Frontiers in medicine · 2025Article
- Case Report: Laparoscopic appendectomy in a patient with congenital visceral heterotaxy and severe adhesions.Frontiers in surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: The aim of the study was to verify the fast recovery effect of transumbilical laparoendoscopic single-site surgery by analyzing the operative and postoperative outcomes of patients with various gynecological malignancies in implementing The Enhanced Recovery After Surgery (ERAS) protocols. Design: A retrospective study. Setting: A university academic hospital. Population or sample: Patients with cervical, endometrial or ovarian cancer undergoing transumbilical laparoendoscopic single-site surgery by a single experienced surgeon. Methods: This was a retrospective consecutive single-center study of patients with cervical, endometrial, or ovarian cancer undergoing transumbilical laparoendoscopic single-site surgery for full surgical staging from November 2017 to January 2022. Main outcome measures: The main outcomes were the perioperative outcomes in various surgeries, including surgery time, estimated blood loss, length of hospital stay, and complications. Results: 315 gynecologic malignant cases successfully experienced transumbilical laparoendoscopic single-site surgery (TU-LESS) between November 2017 and January 2022 in West China Second Hospital were incorporated, including 195 cervical cancers, 85 endometrial cancers and 35 ovarian cancers. The average age for patients is 47.48 (SD = 8.77). 152 (48.25%) patients have a history of previous pelvic and abdominal surgery. The average operating time and blood loss are 273.71 (SD = 87.12) minutes and 166.87 (SD = 237.09) ml, respectively. The average time for the first passage of flatus is 43.68 (SD = 29.75) hours. The hospitalization is 5.30 (SD = 2.42) days on average. Conclusions: TU-LESS can enhance the recovery of patients who suffer from gynecological malignancies by implementing ERAS with fast flatus, less pain, shorter hospitalization and better rehabilitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.